Goldman Sachs Group Inc. Acquires 183,680 Shares of STERIS plc $STE

Goldman Sachs Group Inc. lifted its holdings in shares of STERIS plc (NYSE:STE) by 40.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 633,530 shares of the medical equipment provider’s stock after purchasing an additional 183,680 shares during the period. Goldman Sachs Group Inc.’s holdings in STERIS were worth $160,613,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB grew its holdings in shares of STERIS by 259.0% during the 4th quarter. Nordea Investment Management AB now owns 51,602 shares of the medical equipment provider’s stock valued at $13,165,000 after purchasing an additional 37,228 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of STERIS by 9.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,039,351 shares of the medical equipment provider’s stock valued at $257,157,000 after purchasing an additional 89,250 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of STERIS by 5.3% during the 3rd quarter. Legal & General Group Plc now owns 693,116 shares of the medical equipment provider’s stock valued at $171,505,000 after purchasing an additional 34,981 shares during the last quarter. Elo Mutual Pension Insurance Co bought a new position in shares of STERIS during the 3rd quarter valued at $2,480,000. Finally, Groupama Asset Managment bought a new position in shares of STERIS during the 3rd quarter valued at $1,163,000. Institutional investors own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other STERIS news, Director Richard C. Breeden sold 1,481 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the sale, the director owned 38,964 shares of the company’s stock, valued at $8,163,347.64. This trade represents a 3.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is currently owned by company insiders.

STERIS Price Performance

Shares of STERIS stock opened at $212.13 on Monday. The firm has a market cap of $20.70 billion, a PE ratio of 26.75 and a beta of 0.93. STERIS plc has a 12-month low of $195.14 and a 12-month high of $269.44. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The company’s fifty day simple moving average is $217.24 and its two-hundred day simple moving average is $238.96.

STERIS (NYSE:STE) last announced its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.STERIS’s revenue was up 6.7% on a year-over-year basis. During the same period last year, the business earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities analysts expect that STERIS plc will post 11.18 EPS for the current year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is 31.78%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on STE shares. Piper Sandler reaffirmed an “overweight” rating and set a $270.00 target price on shares of STERIS in a report on Thursday, May 21st. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and an average price target of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.